Advances in immune checkpoint inhibitors combined with other treatments
10.11665/j.issn.1000-5048.20221028002
- VernacularTitle:基于免疫检查点抑制剂的联合治疗策略研究进展
- Author:
Nan YANG
1
;
Xiao ZHANG
;
Hui LYU
;
Meirong HUO
;
Wei XU
Author Information
1. 山东第一医科大学第一附属医院(山东省千佛山医院)药学部
- Publication Type:Journal Article
- From:
Journal of China Pharmaceutical University
2023;54(2):131-140
- CountryChina
- Language:Chinese
-
Abstract:
As one of the most attention-attracting immunotherapy, immune checkpoint inhibitors (ICIs) have been approved as the first-line drugs for the therapy of various types of cancers.Nevertheless, the single application of ICIs exhibited limited efficacy, and it is easy to develop drug resistance.Therefore, the development of combination therapies become a hot topic in this field to improve the efficacy of ICIs therapy.This article describes some new ICIs targets, reveals the mechanisms of resistance, and introduces the current status of combination other therapies with ICIs therapy systematically including chemotherapy, radiotherapy, hyperthermia, antiangiogenic therapy, tumor vaccines, cytokine therapy and adoptive cellular therapy.Furthermore, the synergistic mechanism of combination therapy to enhance antitumor effect.Thus, this article provides solid references for personalized combination therapy according to the pathological characteristics of patients.
